BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 11545544)

  • 21. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression.
    Fong CL; Mok CL; Hui KM
    Gene Ther; 2006 Feb; 13(3):245-56. PubMed ID: 16163376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer vaccines: a critical review on clinical impact.
    Bitton RJ
    Curr Opin Mol Ther; 2004 Feb; 6(1):17-26. PubMed ID: 15011777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
    Conroy H; Marshall NA; Mills KH
    Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trials with tumor antigen genetically modified dendritic cells.
    Ribas A
    Semin Oncol; 2005 Dec; 32(6):556-62. PubMed ID: 16338421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer vaccination.
    Del Vecchio M; Parmiani G
    Forum (Genova); 1999; 9(3):239-56. PubMed ID: 10504171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma.
    Papewalis C; Fassnacht M; Willenberg HS; Domberg J; Fenk R; Rohr UP; Schinner S; Bornstein SR; Scherbaum WA; Schott M
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):215-22. PubMed ID: 16886963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing dendritic cell-based immunotherapy for cancer.
    Zhong H; Shurin MR; Han B
    Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current developments in cancer vaccines and cellular immunotherapy.
    Ribas A; Butterfield LH; Glaspy JA; Economou JS
    J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Dendrite cell-based cancer vaccines--clinical application].
    Svane IM; Berntsen A; Trepiakas R; Pedersen AE
    Ugeskr Laeger; 2006 Apr; 168(14):1415-20. PubMed ID: 16584668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cells and their role in cancer immunotherapy.
    Jalili A
    Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendritic cells in cancer immunotherapy.
    Vulink A; Radford KJ; Melief C; Hart DN
    Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccines: an innovative approach to treating cancer.
    Pazdur MP; Jones JL
    J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
    Bodey B; Siegel SE; Kaiser HE
    In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.
    den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Frielink C; Toonen LW; Boerman OC; Figdor CG; Ruers TJ; Adema GJ
    Br J Cancer; 2006 Oct; 95(7):896-905. PubMed ID: 16953240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy with dendritic cells for cancer.
    Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
    Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.